EUVIMEDEUVIMED entdecken
Crossref

Efficacy of low-dose Escherichia coli-derived recombinant human bone morphogenetic protein-2 in minimally invasive transforaminal lumbar interbody fusion

Tae Hoon Kang, Jeongwoon Han, Minjoon Cho, Jae Hyup Lee

European Spine Journal · 2026

DOI: 10.1007/s00586-025-09600-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Spine Journal, 2026. Verfasst von Tae Hoon Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, College of Medicine, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Spinal Fusion, Bone Morphogenetic Protein 2, Lumbar Vertebrae, Minimally Invasive Surgical Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Seoul Metropolitan Government Seoul National University Boramae Medical Center, the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) offers advantages over open procedures but is limited by the reduced availability of autologous bone. Escherichia coli-derived recombinant human bone morphogenetic protein-2 (E.BMP-2) has emerged as a scalable osteoinductive alternative, though its application in MIS-TLIF remains unstudied. This study aimed to evaluate the efficacy and safety of E.BMP-2 combined with hydroxyapatite (HA) carriers in the context of MIS-TLIF. METHODS: Seventy patients (85 fusion levels) who underwent one- or two-level MIS-TLIF for degenerative lumbar conditions between 2016 and 2024 were included, with a minimum follow-up of one year. The E.BMP-2 group (34 patients, 39 levels) received local bone graft and allogenic cancellous bone graft along with a fixed dose of 1 mg E.BMP-2. The control group (36 patients, 46 levels) received local bone graft and allogenic cancellous bone graft only. Fusion was assessed using dynamic radiographs and CT imaging. Solid fusion on radiographs was defined as segmental motion < 3°, and on CT as continuous trabecular bone bridging between the upper and lower endplates. Clinical outcomes were evaluated using the visual analog scale (VAS) for back and leg pain, the Oswestry Disability Index (ODI), and the Functional Rating Index (FRI). Perioperative and delayed complications-including fever, elevated inflammatory markers, seroma formation, heterotopic ossification, and cage subsidence-were assessed via imaging and medical records. RESULTS: The E.BMP-2 group demonstrated significantly higher fusion rates (radiographs: 97.4% vs. 78.3%, p = 0.001; CT: 89.7% vs. 63.0%, p = 0.005) without an increase in complications. No cases of seroma, heterotopic ossification, or reoperation were observed in the E.BMP-2 group. A standardized application protocol using 1 mg of E.BMP-2 per patient, combined with a containment technique, likely contributed to these favorable outcomes. Although clinical improvements were similar between groups, the rate of cage subsidence was significantly lower in the E.BMP-2 group at 6 and 12 months. CONCLUSION: Low-dose E.BMP-2 appears to be a safe and effective osteoinductive adjunct for MIS-TLIF, particularly in cases with limited autologous bone. Appropriate carrier selection, dosing, and containment techniques are key to optimizing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal FusionBone Morphogenetic Protein 2Lumbar VertebraeMinimally Invasive Surgical ProceduresTransforming Growth Factor betaHumansFemaleMiddle AgedMaleRecombinant ProteinsAgedEscherichia coliTreatment OutcomeBone TransplantationAdult

Stichwörter der Autor:innen

E.coli-derived rhBMP-2Cage subsidenceE.BMP-2Lumbar interbody fusion rateMIS-TLIFRhBMP-2

Substanzen

Bone Morphogenetic Protein 2Recombinant Proteinsrecombinant human bone morphogenetic protein-2Transforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
  • Department of Orthopedic Surgery, College of Medicine, Seoul National University, Seoul, Republic of Korea. spinelee@snu.ac.kr.
  • Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea. spinelee@snu.ac.kr.

Förderung

  • Seoul Metropolitan Government Seoul National University Boramae Medical Center
  • the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)

Zitieren

APA

Kang, T. H., Han, J., Cho, M., & Lee, J. H. (2026). Efficacy of low-dose Escherichia coli-derived recombinant human bone morphogenetic protein-2 in minimally invasive transforaminal lumbar interbody fusion. European Spine Journal. https://doi.org/10.1007/s00586-025-09600-7

Vancouver

Kang TH, Han J, Cho M, Lee JH. Efficacy of low-dose Escherichia coli-derived recombinant human bone morphogenetic protein-2 in minimally invasive transforaminal lumbar interbody fusion. European Spine Journal. 2026. doi:10.1007/s00586-025-09600-7

BibTeX
@article{Kang2026,
  author = {Kang, Tae Hoon and Han, Jeongwoon and Cho, Minjoon and Lee, Jae Hyup},
  title = {Efficacy of low-dose Escherichia coli-derived recombinant human bone morphogenetic protein-2 in minimally invasive transforaminal lumbar interbody fusion},
  journal = {European Spine Journal},
  year = {2026},
  doi = {10.1007/s00586-025-09600-7}
}
Kostenlos starten →